Tata Health International Holdings Limited announced its interim results for the six months ended June 30, 2024. The company reported a revenue of HK$72.3 million, down from HK$104.1 million in the same period in 2023. The gross profit for the period also decreased to HK$55.4 million from HK$85.2 million in the previous year. The company reported a loss before taxation of HK$5.1 million, an improvement compared to the loss of HK$14.3 million reported in the same period last year. The loss attributable to owners of the company was HK$5.1 million, compared to HK$12.3 million in 2023. The gross profit margin decreased from 81.9% to 76.6%, and the loss margin attributable to owners improved from 11.8% to 7.1%. The revenue from the sales of goods was primarily from footwear products, totaling HK$72.3 million, compared to HK$100.7 million in 2023. The sales were mainly through retail channels, which contributed HK$70.3 million, and wholesale channels, which contributed HK$2 million. The company did not report any revenue from online medical services or financial services during the six months ended June 30, 2024. There was no reported outlook or guidance for future periods included in the announcement.